Beijing Huaxia Yisheng Innovation Technology

Beijing Huaxia Yisheng Innovation Technology is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of innovative cell therapies. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) technology to treat various cancers, particularly hematological malignancies like lymphoma and leukemia. Its lead program, HXY-T001, is a dual-target CAR-T therapy designed to mitigate antigen escape by targeting both CD19 and CD22. Huaxia Yisheng maintains integrated R&D and manufacturing capabilities to advance its pipeline of multi-specific and armored CAR-T candidates. The company aims to provide more effective and accessible immunotherapy options for patients with refractory or relapsed malignancies. It operates a state-of-the-art GMP manufacturing facility to support its clinical trials and future commercialization efforts.